Scinai Amends PinCell Option, Seeks €12M Non-Dilutive Grant for PC111 Development
Summary
Scinai Immunotherapeutics has amended its PinCell acquisition option agreement and submitted a revised application for a €12 million non-dilutive grant to fund the development of its PC111 therapeutic candidate, a critical step for the micro-cap company.
Key Events
-
Revised Grant Application Submitted
Scinai submitted a revised application for a €12 million non-dilutive, non-repayable grant under the European FENG SMART Path program. This funding would support an €15 million R&D program for PC111, covering 80% of project costs.
-
PinCell Option Agreement Amended
The binding option agreement for the acquisition of PinCell S.r.l. was amended, extending the deadline for option conditions to August 31, 2026, and the exercise period to September 30, 2026, to align with the grant evaluation process.
-
PC111 Program Advancement
The potential grant funding is intended to advance PC111, a first-in-class therapeutic candidate for pemphigus vulgaris (PV) and Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN), through early clinical development and human proof of concept.
Analysis
This filing highlights Scinai's strategic efforts to secure substantial non-dilutive funding for its PC111 program, a fully human monoclonal antibody targeting severe autoimmune blistering diseases. The potential €12 million grant, representing 80% co-financing for a €15 million R&D program, is highly significant for a company with a very low market capitalization. If awarded, this funding would enable the company to advance PC111 through human proof of concept, preserve balance sheet flexibility, and minimize shareholder dilution, which is crucial given the company's recent Nasdaq compliance issues (as noted in the 2026-03-19 6-K filing). The amendment to the PinCell option agreement directly aligns its timeline with the grant evaluation process, underscoring the importance of this potential funding for the acquisition. Investors should monitor the outcome of the grant application, expected within three to four months, as it could be a transformative event for the company's financial stability and pipeline progression.
At the time of this filing, SCNI was trading at $0.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $603.6K. The 52-week trading range was $0.61 to $6.18. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.